Background: Neural cell adhesion molecule (NCAM) is a glycoprotein and plays an important role in cell-cell adhesion, neural migration, neurite outgrowth, synaptic plasticity and brain development. We investigated the relationship between the serum NCAM concentration and cognitive deficit in first episode drug naïve schizophrenia (FES) patients.
Serum NCAM levels and cognitive deficits in first episode schizophrenia patients versus health controls
Norcross). The sensitivity for NCAM measurement was 0.5pg/ml, with intra-assay coefficients from 3% to 6%. All the samples were assayed in triplicate.
There were no significant differences in age and gender distributions between FES and HC. HC had higher education than FES patients. There was a significantly positive correlation between the education and serum NCAM levels (r=0.362, p=0.005) considering all subjects. Figure 1 shows that the serum NCAM levels were 30% lower in FES patients compared with HC subjects (38.22±12.99 µg/ml vs 54.82±17.03 µg/ml, p<0.001).
Cognitive scores on MCCB were significantly lower in FES patients than healthy controls (87.00±10.58 vs 56.67±12.60, p<0.001). The serum NCAM levels were positively correlated with the total scores of MCCB (r=0.438, p=0.003). Multiple regression analysis confirmed that serum NCAM level was an independent contributor to MCCB total Scores.
The primary findings of this study were that NCAM levels were significantly lower in FES patients than healthy controls, and the decreased serum NCAM levels had a positive correlation with impaired cognitive function, which was an independent contributor to MCCB total Scores. However, several limitations of the study should be noted here. First, we measured NCAM in serum, but not in the cerebral spinal fluid or brain tissues. It was still uncertain whether peripheral NCAM levels can reflect similar changes in the central nervous system. The second was the relatively small sample size in each group. The correlation analyses were performed based on the combined group, future studies should verify these results in lager amount of sample.
Third, the results showed that serum NCAM levels were significantly reduced in drug naïve first-episode patients. However, the effect of antipsychotic drug on NCAM expression still unknown. So, a longitudinal study may be required to examine the levels of NCAM of these FES patients following antipsychotic treatments.
In conclusion, our results demonstrated that FES patients had significantly lower levels of serum NCAM concentration, which were correlated with cognitive deficits.
Since NCAM has an important role in neurodevelopmental processes, these results support the neurodevelopmental dysfunction hypothesis of schizophrenia and suggest that altered NCAM may be one of the biomarkers for schizophrenia, especially for cognitive impairment. 
